Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Q3 Revenues Move up 32 Percent

NEW YORK(GenomeWeb) – Signal Genetics said on Friday that its third quarter revenues increased 32 percent year over year. 

For the three months ended Sept. 30, the Carlsbad, Calif.-based cancer diagnostics firm said that revenues rose to $1.3 million from $983,589 in the year-ago quarter. 

"During the third quarter, we continued to execute on our business strategy by significantly growing our revenue, extending a key partnership and expanding our leadership team," Signal President and CEO Samuel Riccitelli said in a statement. 

During the quarter, the company hired Tamara Seymour as its CFO and Michael Cerio as senior vice president, commercial strategy and business development, and in September, it reached a deal to exclusively provide gene array clinical genetic testing services to the University of Arkansas for Medical Sciences. 

Signal's net loss for the third quarter rose to $1.6 million, or $.43 per share, from a net loss of $879,635, or $.35 per share, a year ago. The company went public in June and used about 3.8 million shares to calculate its loss on a per-share basis for the recently completed quarter, compared to 2.7 million shares in the year-ago period.

Its R&D spending was up to $76,214 from $46,604 year over year, while its SG&A spending more than doubled to $1.3 million from $535,444.

Signal finished the quarter with $6.4 million in cash and $50,236 in restricted cash, it said. 

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.